The consequences of H2 receptor antagonist - piroxicam coadministration in patients with joint disorders

P. A. Milligan, P. E. McGill, Colin Howden, A. W. Kelman, B. Whiting

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine. Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L-1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the % piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period). A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation. No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations.

Original languageEnglish (US)
Pages (from-to)507-512
Number of pages6
JournalEuropean Journal of Clinical Pharmacology
Volume45
Issue number6
DOIs
StatePublished - Dec 1 1993

Fingerprint

Piroxicam
Histamine H2 Receptors
Nizatidine
Joints
Cimetidine
Area Under Curve
Pharmacokinetics
Joint Diseases
Glucuronidase
Non-Steroidal Anti-Inflammatory Agents
Hydroxylation
Cross-Over Studies
Cytochrome P-450 Enzyme System
Albumins
Rheumatoid Arthritis
Urine
Weights and Measures
Pharmaceutical Preparations
5'-hydroxypiroxicam

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

The consequences of H2 receptor antagonist - piroxicam coadministration in patients with joint disorders. / Milligan, P. A.; McGill, P. E.; Howden, Colin; Kelman, A. W.; Whiting, B.

In: European Journal of Clinical Pharmacology, Vol. 45, No. 6, 01.12.1993, p. 507-512.

Research output: Contribution to journalArticle

@article{61b9f53c81674f32afab883e31cac160,
title = "The consequences of H2 receptor antagonist - piroxicam coadministration in patients with joint disorders",
abstract = "A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine. Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L-1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the {\%} piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period). A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation. No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations.",
author = "Milligan, {P. A.} and McGill, {P. E.} and Colin Howden and Kelman, {A. W.} and B. Whiting",
year = "1993",
month = "12",
day = "1",
doi = "10.1007/BF00315306",
language = "English (US)",
volume = "45",
pages = "507--512",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - The consequences of H2 receptor antagonist - piroxicam coadministration in patients with joint disorders

AU - Milligan, P. A.

AU - McGill, P. E.

AU - Howden, Colin

AU - Kelman, A. W.

AU - Whiting, B.

PY - 1993/12/1

Y1 - 1993/12/1

N2 - A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine. Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L-1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the % piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period). A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation. No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations.

AB - A randomised crossover study was performed in subjects with rheumatoid arthritis (or other arthropathies) to investigate if any alteration in the steady pharmacokinetics of the NSAID piroxicam (a drug which is extensively metabolised via cytochrome P450) or its major metabolites occurred as a result of coadministering either cimetidine or nizatidine. Twelve females and 2 males with mean age, weight, and albumin concentrations of 58 years, 61 kg, and 40 g·L-1 respectively, completed the study. Comparisons were made between the following parameters: plasma piroxicam AUCs [AUC0-24(P)], plasma 5-hydroxypiroxicam AUCs [AUC0-24(5-OHP)], the ratio of these i.e. AUC0-24(5-OHP):AUC0-24(p), the % piroxicam daily dose excreted in urine as 5-hydroxypiroxicam (before and after glucuronidase incubation); and the mean of the steady state trough piroxicam, and 5-hydroxypiroxicam concentrations (obtained during each study phase in addition to the wash-out period). A statistically significant difference as a result of initiating either cimetidine or nizatidine was obtained only for the ratio AUC0-23(5-OHP):AUC0-24(P). This was indicative of a weak potential to inhibit piroxicam hydroxylation. No clinically significant alteration in the steady state pharmacokinetics of piroxicam occurred in these subjects as a result of cimetidine or nizatidine coadministration. Consequently it is unlikely that any adverse events would arise from these combinations.

UR - http://www.scopus.com/inward/record.url?scp=0027788310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027788310&partnerID=8YFLogxK

U2 - 10.1007/BF00315306

DO - 10.1007/BF00315306

M3 - Article

C2 - 7908879

AN - SCOPUS:0027788310

VL - 45

SP - 507

EP - 512

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 6

ER -